Ann Ibd. Pg. Med 2022. Vol.20, No.2 160-168

EVALUATION OF PHENOTYPIC AND MOLECULAR TECHNIQUE IN THE DETECTION OF EXTENDED SPECTRUM BETA-LACTAMASE (ESBL)-PRODUCING GRAM NEGATIVE BACILLI IN OGUN STATE, NIGERIA

T.A. Ajani[1], C.J. Elikwu[2] , C.G. Anaedobe[3], C.N. Onwuzo[2], B. Tayo[2], C.C. Okangba[2], O.B. Makanjuola[1,4]

1. Department of Medical Microbiology and Parasitology, University College Hospital, Ibadan, Nigeria.
2. Department of Medical Microbiology, Benjamin Carson (Snr) College of Health and Medical Sciences, Babcock University, Ilisan Remo, Nigeria.
3. Department of Medical Microbiology and Parasitology, College of Health Sciences, University of Abuja, Abuja, Nigeria.
4. Department of Medical Microbiology and Parasitology, University of Ibadan, Ibadan, Nigeria.

Correspondence:
Dr T.A. Ajani
Dept. of Medical Micro. and Parasitology,
University College Hospital,
Ibadan, Oyo State,
Nigeria.
Email: solamustoo@yahoo.com

ABSTRACT

Background: **Molecular diagnosis though faster and more sensitive than phenotypic techniques, is more expensive. Resource limited settings are thus limited to using more of phenotypic rather than molecular methods in the routine detection of Extended Spectrum beta lactamases (ESBL)**

Aim: **This study aimed to evaluate the performance of double disc synergy test (DSST) and Epsilometer (E) test with Polymerase Chain Reaction (PCR) and to detect the risk factors associated with ESBL producing organisms among in-patients at Babcock University Teaching Hospital, Ilishan-Remo, Nigeria.**

Methodology: **Hospital-based cross-sectional study in which bacterial isolates of 165 in-patients were collected fromMarch 2018 to September 2019. The isolates were evaluated for ESBL production by the use of DDST, Etest and PCR. The performance evaluation was done. Questionnaire was used to assess the risk factors associated with ESBL, IBM SPSS Version 23 was used to analyze the data.**

Results: **The participants' isolates yielded 50/165 (30.3%) that were ESBL positive by DDST, 47/165 (28.9%) by E-test and 48/165(29.1%) by PCR. Sensitivity and specificity of DSST was 100% and 98.3% while that of E-test was 98% and 100% respectively. Age, antibiotics intake without prescription, being on ventilator, urethral catheterization and nasogastric tubes were all significantly associated with presence of ESBL (p value <0.05).**

Conclusion: **Phenotypic tests remain reliable for the routine detection of ESBL in the absence of molecular methods. Rational use of instrumentation and antibiotics is advocated based on the risk factors detected from this study.**

Keywords: Double disc synergy test, Epsilometer test, Polymerase Chain Reaction (PCR), Extended spectrum beta lactamases.

INTRODUCTION

The continued increase in the prevalence of multi-drug resistant organisms (MDRO) is a known cause of therapeutic failures clinically and this has become a major global concern.[1,2] Among the MDRO, of most importance are Gram-negative bacilli producing Extended Spectrum beta lactamases (ESBL). These organisms cause a large proportion of infections both in the hospital and community but are resistant to most common treatment options including Beta lactam antibiotics.[3-5] Therefore resistance of Gram-negative bacilli to these antibiotics is a public health concern because of limited therapeutic options in infected patients.[1]

ESBL hydrolyzes penicillin, narrow- and extended-spectrum cephalosporins and aztreonam but they are inhibited by beta lactam inhibitors.[5-7] Also, the presence of ESBL in a bacterium can confer resistance to trimethoprim-sulphamethoxazole, aminoglycosides and quinolones because the plasmids carrying ESBL genes are also known to carry resistance genes that encode for resistance to other antibiotics.[5-7] The high transferability of plasmids carrying ESBL genes has increased the risk of resistance transmission in hospital infections leading to prolonged hospital stay, increased medical bills and adverse disease outcomes in patients. All these have made ESBL a serious threat globally.[3,7-8]

ESBLs are prevalent worldwide and the prevalence has continued to escalate over the years.[2,8] In 2017, the Centers for Disease Control and Prevention (CDC) estimated that among hospitalized patients, there were 197,400 cases of ESBL-producing enterobacteriaceae and 9,100 estimated deaths in the United States alone.[9] In Chitwan, South Asia, the prevalence of ESBL was reported to be 64% while in Pakistan the prevalence of ESBL has been increasing over the last decade and is reported to be 79%.[1,10] In Sub-Saharan Africa, ESBL has been reported to be a major public health threat with a prevalence of 62.3% in Mali and 64.3% in Sierra Leone.[11] In Nigeria, the prevalence of ESBL varies from 23.6% in Maiduguri, 11.4% in Enugu to 51.3% in Ile-Ife.[12-14]

Laboratory methods for the detection of ESBL include the phenotypic and molecular methods.[15] Phenotypic methods include the use of double disc synergy test (DDST), Epsilometer (E test) and Combination disc method which are based on the inhibitory activities of beta-lactamase inhibitors.[3,15-16] These methods are the preferred options in the routine medical microbiology laboratory because of the cheaper cost.[3] However, these methods have longer turnaround time, depending on bacterial growth, the results are subjective and there may be the issue of false positivity or false negativity if the ESBL-producing bacteria coexpress AmpC type β-lactamase (ACBL).[17,18]

Molecular diagnosis is faster, more accurate and more sensitive than phenotypic techniques thereby improving treatment outcomes in patients and is also useful in supplying epidemiological data.[17,19] Recently, the Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) reduced the susceptibility breakpoints of Cephalosporins therefore making the of use phenotypic ESBL tests routinely unnecessary.[3,16] However, considering the lack of precision that might accompany antimicrobial susceptibility test and also that in-vitro susceptibility may not translate to clinical success in the therapeutic management of patient, confirmatory phenotypic ESBL tests might still be necessary routinely.[3,20] Though rapid and accurate detection of ESBL is needed for appropriate essential antibiotic treatment and infection control activities and the molecular or automated methods fit perfectly for this, however, they are more costly and need trained personnel. Therefore, most laboratories in developing countries cannot afford to employ these methods.[21] This leaves us with the option of using more phenotypic methods than automated or molecular methods in the detection of ESBL. Therefore, it is important to carry out performance evaluation of phenotypic methods as against the molecular methods in our environment. Thus the objective of this study was to evaluate the performance of the double disc synergy test and E-test by comparing with PCR and also to detect the risk factors associated with ESBL among in patients in Babcock University Teaching Hospital, Ilishan-Remo, Nigeria.

MATERIALS AND METHODS

This was a descriptive cross-sectional study conducted from March 2018 to November 2019 among in-patients of Babcock University Teaching Hospital, Ilisan-Remo, Ogun State.

The sample size, 165 was calculated by Leslie fisher's formula[22] and the prevalence used was 11.4% from a study in Enugu, Nigeria.[23] Participants were recruited by simple random sampling and inclusion criteria was the in-patients diagnosed with clinical infections while those unwilling to fill the questionnaire or give permission for specimen collection were excluded. Written informed consent was obtained from each participant after a semi-structured interviewer-administered questionnaire was used to obtain sociodemographic and associated predisposing factors to ESBL infection. Ethical approval with ethical clearance number BUHREC070/18 was obtained from Babcock University Health Research ethics committee Ilishan-Remo, Ogun State, Nigeria. The date of the approval was 28th of February, 2018. Data was collected from March 2018 to September 2019. Specimens such as blood culture, sputum, urine, wound biopsy, swabs, cerebrospinal fluid and/or aspirates were collected from the participants, as indicated, and processed in the Medical Microbiology laboratory by following standard microbiology procedures.[24] The organisms were identified by Microbact TM GNB 24E (Oxoid®, Basingstoke, UK) The Kirby-Bauer disc diffusion method was used for the antimicrobial susceptibility test and the Clinical and Laboratory Standards Institute (CLSI) chart was used for interpretation.[25-26] *Klebsiella pneumoniae* ATCC 700603 and *Escherichia coli* ATCC 25922 were the positive and negative control strains respectively.[12,25-26] All isolates resistant to one or more third generation Cephalosporin were subjected to phenotypic testing by double disc synergy test and Epsilometric test (E-test) for confirmation of ESBL-production.[27,28]

The double disc synergy test was done according to CLSI guidelines while the E-test (Biomerieux SA) was done with a cefotaxime gradient at one point and cefotaxime plus clavulanate gradient at the other end.[26,27] The procedure and interpretation were done according to the manufacturer's instruction.[27] DNA extraction was done by a DNA extraction kit, quick- DNA fungal/

bacteria miniprep (Zymo research, USA). ESBL genes SHV and TEM were identified and amplified by the conventional PCR method using previously described primers.[12,28] SHV-F-CGCCTGTGTATTATCTCCCT, SHV-R-C, GAGTAGTCCACCAGATCCT at 293bp, TEM-F-TTTCGTGTCGCCCTTATTCC, TEM-R-ATCGTTGTCAGAAGTAAGTTGG at 403bp.

The amplification was carried out by initial denaturation at 94^0C for 5 minutes, followed by 35 cycles of denaturation at 94^0C for 15 seconds, annealing temperature of 55^0C for 20 seconds, followed by extension at 72^0C for 30 seconds and another extension at 72^0C for 7 minutes. Subsequently, the amplified PCR products were separated 1.5% electrophoretic agarose gel.

In comparison to PCR, the performance of DDST was evaluated for true positive (Number of isolates that were DDST positive where PCR was positive), False negative (Number of isolates that are DDST negative but PCR positive), True negative (Number of isolates that are DDST negative where PCR was negative) and False positive (Number of isolates that are DDST positive but PCR negative). The same performance evaluation was done for E-test respectively. Then sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of each test was calculated respectively. The study data was analysed by SPSS version 23 software.

RESULTS

The 165 isolates from various clinical specimens of the participants yielded 50 (30.3%) isolates that were ESBL positive by double disc synergy test, 47 (28.9%) by E test and 48(29.1%) by PCR.

SHV gene was 37/48(77.1%) (Figure 1) while TEM was 24/48(50%) (Figure 2) while 13 were overlapped 13/48(27.1%)

The 47 isolates positive by E test were also positive with DDST. Taking PCR as the standard, the comparison of the result of the double disc synergy test with PCR and E test with PCR is presented in Table 1.

The sensitivity, specificity, positive predictive value (PPV), Negative predictive value (NPV) and accuracy of DDST was 100%, 98.3%, 96%, 100% and 97.6% respectively while that of E test was 98%, 100%, 100%,

Table 1: Comparison of the prevalence of ESBL in participants by using DDST, E test and PCR

Variables	PCR		Total
	Positive (%)	Negative (%)	
DDST			
Positive	48(96.0)	2(4.0)	50
Negative	0(0.0)	115(100)	115
E- test			
Positive	47(100)	0(0.0)	47
Negative	1(0.8)	117(99.2)	118

DDST: Double Disc Synergy Test, E test: Episilometer test

Table 2: Prevalence of ESBL-producing organisms

Organisms Isolated	ESBL		Total (%)
	Positive(%)	Negative(%)	
Hafnia alvei	6(75.0)	2(25.0)	8(4.8)
Escherichia coli	6(16.2)	31(83.8)	37(22.4)
Klebsiella pneumoniae	13(50.0)	13(50.0)	26(15.8)
Serratia liquefaciens	3(37.5)	5(62.5)	8(4.8)
Enterobacter sakazakii	2(33.3)	4(66.7)	6(3.6)
Enterobacter cloacae	2(25.0)	6(75.0)	6(3.6)
Acinetobacter lwoffii	2(33.3)	4(66.7)	6(3.6)
Acinetobacter haemolyticus	1(33.3)	2(66.7)	3(1.8)
Klebsiella oxytoca	3(14.3)	18(85.7)	21(12.7)
Acinetobacter baumanii	4(66.7)	2(33.3)	6(3.6)
Klebsiella ozaenae	2(28.6)	5(71.4)	7(4.2)
Enterobacter gergoviae	0(0.0)	7(100.0)	7(4.2)
serratia marcescens	0(0.0)	7(100.0)	7(4.2)
pseudomonas	4(57.1)	3(42.9)	7(4.2)
Organisms isolated but not significant	0(0.0)	8(100.0)	8(4.8)
Total	**48(29.1)**	**117(70.9)**	**165(100.0)**



Figure 1: SHV gene amplicon



Figure 2: TEM gene amplicon

Table 3: Probability of organism isolated to be ESBL positive

Organism isolated/NO	P-value	OR (95% CI)
Hafnia alvei /8	0.008	17.8(2.13-149.23)
Escherichia coli /37	0.81	1.2(0.24-6.18)
Klebsiella pneumonia /26	0.021	6.3(1.32-30.27)
Serratia liquefaciens / 8	0.17	4.1(0.55-30.87)
Enterobacter sakazakii /6	0.28	3.4(0.37-31.32)
Enterobacter cloacae /8	0.45	2.3(0.27-19.40)
Acinetobacter lwoffii /6	0.28	3.4(0.37-31.32)
Acinetobacter haemolyticus /3	0.39	3.4(0.21-55.70)
Klebsiella oxytoca /20	0.95	0.9(0.15-5.91)
Acinetobacter baumanii /6	0.021	13.7(1.49-125.28)
Klebsiella ozaenae / 7	0.36	2.7(0.31-23.98)
Pseudomonas aeruginosa /7	0.018	9.8(1.48-64.95)

99.2% and 99.4% respectively. This is illustrated in Figure 3

The highest proportion of ESBL producers was found among *Hafnia alvei* and *Klebsiella pnuemoniae*. (Table 2). In contrast, no ESBL producers were found in *Enterobacter gergoviae* and *Serratia marcescens*.

Hafnia alvei, *Escherichia coli*, *Klebsiella pneumoniae*, *Klebsiella oxytoca* and *Acinetobacter baumanii* were more likely to produce ESBL. (p value < 0.05). This is seen in Table 3.

Age, level of Education, history of unconsciousness, recent past hospital admission, recent past ICU admission, history of taking antibiotics without



Keywords
DDST- Double disc synergy test
E test-Epsilometertest
PPV-positive predictive value
NPV- Negative predictive value

Figure 3: Performance evaluation of DDST and E test

prescription, being on ventilator, urethral catheterization and nasogastric tubes were all statistically significantly associated with ESBL.(p value < 0.05). (Table 4).

Table 4: Risk factors associated with ESBL among the participants

Variables	ESBL		P-value	X^2	Df
	Positive (%)	Negative (%)			
Age (Years)					
1-10	3(75.0)	1(25.0)			
11-20	6(75.0)	18(25.0)			
21- 30	9(14.5)	53(85.5)	0.00	27.6	7
31-40	8(24.2)	25(75.8)			
41- 50	7(25.0)	21(75.0)			
51-60	3(20.0)	12(80.0)			
61- 70	4(44.4)	5(55.6)			
71-80	8(100.0)	0(0.0)			
Sex					
Male	28(33.7)	55(66.3)	0.19	1.75	1
Female	20(24.4)	62(75.6)			
Marital status					
Single	15(26.8)	41(73.2)	0.64	0.22	1
Married	33(30.3)	76(69.3)			
Level of Education					
No school	7(58.3)	5(41.7)			
Primary	6(28.6)	15(71.4)	0.07	7.08	3
Secondary	11(20.4)	43(79.6)			
Tertiary	24(30.8)	54(69.2)			
History of unconsciousness			0.00	23.20	1
Yes	9(100.0)	0(0.0)			
No	39(25.0)	117(75.0)			
Recent past hospital admission			0.00	27.09	1
Yes	27(58.7)	19(41.3)			
No	21(17.6)	98(82.4)			
Long ICU stay			0.00	16.5	1
Yes	8(88.9)	1(11.1)			
No	40(25.6)	116(74.4)			
Antibiotics without prescription			0.00	26.29	1
Yes	18(72.0)	7(28.0)			
No	24(20.7)	92(79.3)			
On ventilator			0.00	15.18	1
Yes	6(100.0)	0(0.0)			
No	42(26.4)	117(73.6)			
Urethra Catheter			0.00	52.9	1
Yes	32(71.1)	13(28.9)			
No	16(13.3)	104(86.7)			
On Nasogastric tube					
Yes	15(60.0)	10(40.0)	0.00	13.65	1
No	33(23.6)	107(76.4)			

DISCUSSION

Phenotypic ESBL detection tests have been linked with varying sensitivities and specificities depending on location, species and settings.[20] In our hospital setting, the use of phenotypic tests to detect ESBL is easier and cost effective, hence the need for us to evaluate these tests against the molecular test which is considered the gold standard.[17,19]

In this index study, the sensitivity of DDST was 100% while that of the E test was 98% compared with PCR testing. These high sensitivities indicate that these tests have good utility in identifying ESBL producing organisms. However, it appears that the E test is more sensitive than DDST in detecting ESBL in these isolates. This finding is similar to what was reported by Sedlakova *et al.* in which the sensitivity of DDST was 100% and the E test was 95%.[16] However, Kaur and Aruna reported that there is no difference between

the sensitivities of these two methods.[30] Variations in these reports can be attributed to use of different disks. False positive ESBL tests can result in a falsely high ESBL prevalence rate and create restricted therapeutic options for patients who may have to resort to taking Carbapenems. Minimizing such errors is therefore very important for appropriate patient therapy. One of the ways of reducing false positivity is the use molecular tests, which though are more accurate, are too expensive to perform routinely in developing countries like ours.[17,19,20-21] We found that both DDST and E test had high specificities, with E-test having no false positive isolate, and DDST is only slightly less specific at 98.5%.

The new CLSI guidelines and EUCAST breakpoints for Cephalosporin have reduced the rate of false positivity by the new cephalosporin breakpoints up to a level.[16] The current CLSI guidelines recommends that routine confirmatory phenotypic test for ESBL is not necessary but some authors have argued that a low cephalosporin MIC alone is not a clear predictor of therapeutic clinical success especially in some group of patients with altered antibiotic pharmacokinetics and high risk of therapeutic failure. Thus, the knowledge of confirmatory ESBL status is very important.[30, 31]

Our findings of the positive and negative predictive values (PPV and NPV) of DDST and the E test show that both have high and acceptable values. We also noted based on these results that E test is more reliable when the result is ESBL-positive (100% vs 96%) while an ESBL-negative result is only slightly more reliable when DDST is carried out (100% vs 99.2%). This finding is similar to what was reported by Morrisey *et al.*[30]

Also, in developing countries where routine antimicrobial susceptibility testing may not be done with enough accuracy or precision to stratify isolate into whether they are resistant, intermediate or susceptible, there may still be a need to perform the confirmatory phenotypic ESBL tests.[20]

Overall, our study demonstrates the efficacy of the DDST and the E tests in ESBL detection, especially in resource constrained settings like ours. Although the two tests evaluated showed comparable performance, the E test might not be a feasible method to use routinely because it is more expensive than DDST to carry out. Therefore, DDST might seem to be the most feasible and effective method in developing countries. It should however be borne in mind that there can be false positivity and false negativity, if the isolate co-expresses Amp C.

The prevalence of phenotypic ESBL prevalence varies across the world.[2, 8] In this study, the ESBL prevalence by DDST was 30.3% which is similar to previous reports by Olorunitola and colleagues and Halaji *et al.* with DDST which reported 30% and 31.3% respectively.[32-33] Other prevalence reported by DDST includes 38.18% by Numanovic *et al.*, 51.3% by Bajpai *et al.*, 54% by Ejaz, 5% by Yusuf *et al.* in kano, Nigeria and 34.3% in in Zaria by Giwa *et al.*[15,21,34-35]

The E test ESBL positivity was 28.9% from this index study and its lower than the 61% reported by Abrar *et al.* and Moharty *et al.* respectively.[1,36] Although it is higher than 14% by Chandramohan and Revell by the use of the same methods.[37] Our PCR prevalence is 29.1% which is lower than 52.49% by Sharma *et al.* and higher than 7% by Chandramohan and Revelli by the use of a similar method.[19,38] These discrepancies across the world are most likely caused by geographical locations, type of isolates, diagnostic methods employed, the precision of laboratory procedures, various patients' characteristics, use and misuse of antibiotics.[2,21,33,39] A major conclusion from all these variations is the necessity for the use of molecular methods which will give a definitive result of ESBL. Unfortunately, these might not be realistically carried out routinely in developing countries because it is costly and requires expensive equipment and well-trained personnel.[21]

Klebsiella pneumoniae has been reported in many studies to harbor more ESBL and this report is similar to what was found in this index study.[14,29,40] Although some other literature reported contrary findings.[35, 41] The variations in these reports suggest that many bacteria are now harbouring ESBL and this is a serious threat to patient's management. Some of the Enterobacter species in this study were ESBL positive and this finding is congruent to previous reports by Aibinu *et al.* and Akujobi and Ewuru respectively.[42-43] However, Yusuau and colleagues did not find ESBL in their confirmed Enterobacter isolates.[44] *Hafnia alvei*, though an uncommon pathogen, was observed to harbour a very high proportion of ESBL. It is therefore necessary to closely monitor the emergence of this organism as a pathogen especially in the hospital environment. *Serratia marcescens* did not harbour ESBL in this present study and this finding is consistent with that of Nwankwo *et al.* in Kano.[45]

An understanding of risk factors is important for instituting measures to prevent infections with ESBL-producing organisms. Risk factors found to be associated with ESBL production in this study includes unconsciousness, long ICU stay, recent hospital admission, use of antibiotics without prescription, use

of a urethral catheter, being on ventilator and use of ventilators. Some of these risk factors have been reported previously by some authors to be associated with ESBL.[29,46,47] Age is associated with ESBL in this present study as the risk of ESBL-producing organisms was much higher in children and the elderly. This finding is contrary to previous studies by Maleki *et al.* and Moini *et al.* but it is consistent with reports from Sabrina *et al.* and Jewoola *et al.* in Nigeria. Gender was not an associated risk factor in this study and these findings are congruent with Maleki *et al.* and Moini *et al.* but contrary to Ibrahim *et al.*[39, 48, 49]

The limitation of this study includes the non-differentiation of colonizers from pathogens, limited ESBL genes were evaluated and we did not carry out sequencing to identify probable mechanism of resistance.

CONCLUSION

The prevalence of ESBL by DDST, E test and PCR was 50 (30.3%), 47 (28.9%) by E test and 48(29.1%) respectively. Compared to PCR, which is the standard, the sensitivity and specificity of DDST were 100%, and 98.3% while that of E test was 98% and 100% respectively.

Although the molecular methods are more sensitive and accurate, they are expensive to carry out routinely and based on the findings of specificity and sensitivity from this study, we advocate that the phenotypic tests, DDST and the E test, can still be used for routine detection of ESBL in our environment. They however, need to be evaluated periodically to confirm adequate performance. Based on the identified risk factors, rational use of antibiotics and minimization of instrumentation are advocated in patients.

Conflicts of Interest

There are no conflicts of interest.

REFERENCES

1. **Abrar S,** Noor UA, Huma L, *et al.* Distribution of blaCTX " M, blaTEM, blaSHV and blaOXA genes in Extended-spectrum-âlactamase-producing Clinical isolates: A three-year multi-center study from Lahore, Pakistan. *Antimicrob. Resis and Infect Control.* 2019;8:80a
2. **Gholipour A,** Soleimani A, Shokri D, *et al.* Phenotypic and Molecular Characterization of Extended-Spectrum â-Lactamase Produced by Escherichia coli, and Klebsiella pneumoniae Isolates in an Educational Hospital. *Jundishapur J Microbiol.* 2014; 7(10): e11758.
3. **El-Jade MR,** Parcina M, Schmithausen RM, *et al.* ESBL Detection: Comparison of a Commercially Available Chromogenic Test for Third Generation Cephalosporine Resistance and Automated Susceptibility Testing in Enterobactericeae. *PLoS ONE* 2016;11(8): e0160203.
4. **Upendra TS,** Sabnum S, Nabaraj A, *et al.* Plasmid Profiling and Occurrence of â-Lactamase Enzymes in Multidrug-Resistant Uropathogenic *Escherichia coli* in Kathmandu, Nepal.*Infect Drug Res.* 2020; 13: 1905–1917
5. **Gautam V,** Thakur A, Sharma M, *et al.* Molecular characterization of extended-spectrum â-lactamases among clinical isolates of *Escherichia coli* & *Klebsiella pneumoniae*: A multi-centric study from tertiary care hospitals in India. *Indian J Med Res.* 2019;149(2):208-215
6. **Jena J,** Sahoo RK, Debata NK, Subudhi E Prevalence of TEM, SHV, and CTX-M genes of extended-spectrum â-lactamase-producing Escherichia coli strains isolated from urinary tract infections in adults. *3Biotech.* 2017 ;7(4): 244.
7. **Rajaee Behbahani M,** Keshavarzi A, Pirbonyeh N, *et al.* Plasmid-related â-lactamase genes in *Pseudomonas aeruginosa* isolates: a molecular study in burn patients. *J Med Microbiol.* 2019;68(12):1740-1746.
8. **Flokas ME,** Karanika S, Alevizakos M, Mylonakis E. Prevalence of ESBL-Producing Enterobacteria -ceae in Pediatric Bloodstream Infections: A Systematic Review and Meta-Analysis. *PLoS One.* 2017;12(1): e0171216.
9. Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases. ESBL-producing Enterobacteriaceae in Healthcare Settings., 2019. [cited May, 2020]. Available from: https://www.cdc.gov/hai/organisms/ESBL.htm
10. **Shrestha A,** Manandhar S, Pokharel P, *et al.* Prevalence of extended spectrum beta-lactamase (ESBL) producing multidrug resistance Gram-negative isolates causing urinary tract infection. *EC Microbiol.* 2016;4(5):749–755
11. **Afolabi D,** Sogbo F, Haag1 U, *et al.* "Extended-Spectrum Beta-Lactamase (ESBL) - Producing Enterobacteriaceae Isolated in Cotonou: Characteristics and Risk Factors". *EC Bacteriology and Virology Research* 2017; 2(6)210-215.
12. **Mohammed Y,** Gadzama GB, Zailani SB, Aboderin AO. Characterization of Extended-Spectrum Beta-lactamase from Escherichia coli and Klebsiella Species from North Eastern Nigeria. *J Clin Diagn Res.* 2016;10(2): 07-10
13. **Iroha 1,** Adikwu MU, Esimone CO, *et al.* Extended spectrum Beta - Lactamase (EBSL) in E.coli isolated from a tertiary hospital in Enugu state, Nigeria. *Parkistan J. Med. Science* 2009;25 (2):279-282.

14. **Olowe OA,** Oladipo GO, Makanjuola OA, Olaitan JO. Prevalence of extended spectrum beta-lactamases (ESBLS) carrying genes in klebsiella spp from clinical samples at Ile-Ife, South Western Nigeria.*Intl J. pharma Med. Boil. Scien* 2012; 1(2): 01-10
15. **Numanovic F,** Hukic M, Delibegovic Z, Tihic N, Pasic S, Gegic M. Comparison of double disk synergy test, VITEK 2 and CheckMDR CT102 for detection of ESBL producing isolates. *Acta Medica Academica* 2013;42(1):15-24.
16. **Sedlakova MH,** Hanulik V, Chroma M, *et al.* Phenotypic detection of broad-spectrum beta-lactamases in microbiological practice. *Med Sci Monit*. 2011; 17(5): 147–152
17. **Zalas-Wiecek P,** Gospodarek-Komkowska E, Smalczewska A. Rapid Detection of Genes Encoding Extended-Spectrum Beta-Lactamase and Carbapenemase in Clinical Escherichia coli Isolates with eazyplex SuperBug CRE System. *Microbial drug resistance*. 2019; 0(0):202
18. **Tsui K,** Wong SS, Lin LC, *et al.* Laboratory identification, risk factors, and clinical outcomes of patients with bacteremia due to Escherichia coli and Klebsiella pneumoniae producing extended-spectrum and AmpC type â-lactamases. *J Microbiol Immunol Infect*. 2012;45 (3): 193-199.
19. **Sharma M,** Pahak S, Srivastava P. Prevalence and antibiogram of Extended Spectrum â-Lactamase (ESBL) producing Gram negative bacilli and further molecular characterization of ESBL producing Escherichia coli and Klebsiella spp.*J Clin Diagn Res*. 2013; 7(10): 2173–2177
20. **Lob SH,** Biedenbach DJ, Badal RE, *et al.* Discrepancy between genotypic and phenotypic extended-spectrum b-lactamase rates in Escherichia coli from intra-abdominal infections in the USA. *J. Med. Microbiol.* 2016, 65, 905–990
21. **Bajpai T,** Pandey M, Varma M, Bhatambare G S. Prevalence of TEM, SHV, and CTX-M Beta-Lactamase genes in the urinary isolates of a tertiary care hospital.*Avicenna J Med.*2017 ; 7(1): 12–16
22. **Araoye MO.** Subjects selection. In research methodology with statistics for Health and Social Sciences. Ilorin, Nigeria: Nathadex Publishers 2003; 115-129.
23. **Iroha IR,** Adikwu MU, Esimone CO, *et al.* Extended spectrum Beta - Lactamase (EBSL) in E.coli isolated from a tertiary hospital in Enugu state, Nigeria. *Parkistan J. Med. Science*. 2009;25 (2): 279-282
24. **Barrow G.I,** Felthham R.K.A (1993) Cowan and Steele's Manual for the Identification of Medical Bacteria, 3rd Edition. Cambridge: Cambridge University Press.
25. **Bauer A.W.** Antibiotic susceptibility testing by a standardized single disc method. *American J Clini Pathol.* 1966; 44: 493-496
26. **Patel JB,** Weinstein MP, Eliopoulos GM, *et al.* Performance standards for antimicrobial susceptibility testing M100, 27th edition. Wayne, PA: Clinical and laboratory standards institute. 2017.
27. **Moyo SJ,** Aboud S, Kasubi M, *et al.* Antimicrobial resistance among producers and non-producers of extended spectrum beta-lactamases in urinary isolates at a tertiary Hospital in Tanzania. *BMC Res Notes* 2010; 3: 348
28. **Iroha, I.R.,** Esimone, C.O., Neumann, S. First description of Escherichia coli producing CTX-M-15- extended spectrum beta lactamase (ESBL) in out-patients from south eastern Nigeria. *Ann Clin Microbiol Antimicrob*. 2012; 11-19.
29. **Kaur M,** Aggarwal A. Occurrence of the CTX-M, SHV and the TEM Genes Among the Extended Spectrum â-Lactamase Producing Isolates of Enterobacteriaceae in a Tertiary Care Hospital of North India.*J Clin Diagn Res*. 2013 ; 7(4): 642–645.
30. **Morrissey I.,** Bouchillon S.K., Hackel M., *et al.* Evaluation of the clinical and laboratory standards institute phenotypic confirmatory test to detect the presence of extended-spectrum b-lactamases from 4005 Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae and Proteus mirabilis isolates. *J Med Microbio.* 2014; 63(l) : 556–561
31. **Kavi J.,** Bhattacharjee D., Macve J. & Weinbren M.J. Comment on: Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly? *J Antimicrob Chemother.* 2013; 68: 246
32. **Olorunitola OS,** Olayinka AT, Inabo HI, Shaibu AM. Production of Extendedspectrum beta lactamases of urinary isolates of Escherichia coli and Klebsiella pneumonia in Ahmadu Bello University Teaching Hospital, Zaria, Nigeria.*Int.J. Biological Chemistry* 1(2):181-185
33. **Halaji M,** Shahidi S, Atapour A, *et al.* Characterization of extended-spectrum β-Lactamase - Producing Uropathogenic *Escherichia coli* among Iranian kidney transplant patients. *Infect Drug Resist*. 2020;13:1429-1437.
34. **Ejaz H.** Detection of extended-spectrum â-lactamases in *Klebsiella pneumoniae*: Comparison of phenotypic characterization methods. *Pak J Med Sci.* 2013;29(3):768.
35. **Yusuf I,** Haruna M, Yahaya H. Prevalence and antibiotic susceptibility of AmpC and Esbl producing clinical isolates at a tertiary health care center in Kano, Northwest Nigeria. Afr. *J. Cln. Exper. Microbiol.* 14(2): 109-119.

36. **Giwa FJ,** Ige OT, Haruna DM, *et al.* Extended-Spectrum beta-lactamase production and antimicrobial susceptibility pattern of uropathogens in a Tertiary Hospital in Northwestern Nigeria. *Ann Trop Pathol.* 2018 ;9:11-16.
37. **Mohanty S,** Gaind R, Ranjan R, Deb M. Use of the cefepime-clavulanate ESBL Etest for detection of extended-spectrum beta-lactamases in AmpC co-producing bacteria. *J Infect Dev Countr.* 2009; 4 (01):024–029
38. **Chandramohan L,** Revell PA. Prevalence and molecular characterization of extended-spectrum-â-lactamase-producing Enterobacteriaceae in a pediatric patient population. *Antimicrob Agents Chemother.* 2012;56(9):4765-4770.
39. **Maleki N,** Tahanasab Z, Mobasherizadeh S, *et al.* Prevalence of *CTX-M* and *TEM* â-lactamases in *Klebsiella pneumoniae* Isolates from Patients with Urinary Tract Infection, Al-Zahra Hospital, Isfahan, Iran. *Adv Biomed Res.* 2018;7:10.
40. **Shah AA,** Hasan F, Ahmed S, Hameed A. Prevalence of extended spectrum B-lactamases in nosocomial and outpatients (ambulatory) *Pak J Med Sci.* 2004;19:187–191.
41. **Hawser SP,** Bouchillon SK, Hoban DJ, *et al.* Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007. *Antimicrob Agents Chemother.* 2009;53(8):3280-3284.
42. **Akujobi CN,** Ewuru CP. Detection of extended spectrum beta-lactamases in gram negative bacilli from clinical specimens in a teaching hospital in South eastern Nigeria. *Niger Med J* [serial online] 2010; 51:141-146
43. **Aibinu I.,** Fashae K., Ogunsola F., *et al.* Extended-Spectrum Beta-Lactamase (ESBL) in *Klebsiella pneumoniae* isolates from septicaemic children in Ibadan, Nigeria. *Nig. J. Health and Bio. Sci.* 2004: 3(2); 79-78.
44. **Yusha'u Aliyu H.M,** Kumurya A, Suleiman K. Prevalence of extended spectrum â- lactamase (ESBLs) among Enterobacteriaceae in Muritala Mohammed specialist hospital, Kano, Nigeria. Bayero Journal of Pure and Applied Sciences. 2010; 3 (1):169- 172
45. **Nwankwo E.O,** Magaji N.S, Tijjani J. Antibiotic susceptibility pattern of extended spectrum betalactamase (ESBL) producers and other bacterial pathogens in Kano, Nigeria. *Trop J Pharm Res.* 2015; 14(7): 1273
46. **Alves M.,** Lemire A., Decré D, *et al.* Extended-spectrum beta-lactamase "producing enterobacteriaceae in the intensive care unit: acquisition does not mean cross-transmission. *BMC Infect Dis.* 2016; 16: 147
47. **Serefhanoglu K,** Turan H, Timurkaynak FE, Arslan H. Bloodstream infections caused by ESBL-producing E. coli and K. pneumoniae: risk factors for multidrug-resistance. *Braz J Infect Dis.* 2009;13(6):403–407
48. **Moini AS,** Soltani B, Taghavi Ardakani A, *et al.* Multidrug-Resistant Escherichia coli and Klebsiella pneumoniae Isolated From Patients in Kashan, Iran. *Jundishapur J Microbiol.* 2015;8(10):e27517.
49. **Ibrahim ME,** Bilal NE, Hamid ME. Increased multi-drug resistant Escherichia coli from hospitals in Khartoum state, Sudan. *Afr Health Sci.* 2012; 12: 368–375.